Cross Shawn 4
4 · Pacira BioSciences, Inc. · Filed Dec 11, 2025
Insider Transaction Report
Form 4
Cross Shawn
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-09$16.45/sh+15,896$261,489→ 72,146 total - Sale
Common Stock
2025-12-09$25.03/sh−15,896$397,877→ 56,250 total - Exercise/Conversion
Common Stock
2025-12-10$16.45/sh+9,104$149,761→ 65,354 total - Sale
Common Stock
2025-12-10$25.14/sh−9,104$228,875→ 56,250 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-09−15,896→ 184,104 totalExercise: $16.45Exp: 2034-11-04→ Common Stock (15,896 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-10−9,104→ 175,000 totalExercise: $16.45Exp: 2034-11-04→ Common Stock (9,104 underlying)
Footnotes (4)
- [F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.30, inclusive.
- [F4]The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.